Burden of liver disease in the United States: Summary of a workshop
2002; Lippincott Williams & Wilkins; Volume: 36; Issue: 1 Linguagem: Inglês
10.1053/jhep.2002.34734
ISSN1527-3350
AutoresW. Ray Kim, Robert S. Brown, Norah A. Terrault, Hashem B. El–Serag,
Tópico(s)Liver Diseases and Immunity
ResumoHepatologyVolume 36, Issue 1 p. 227-242 Special ArticleFree Access Burden of liver disease in the United States: Summary of a workshop W. Ray Kim 200 First St., Corresponding Author W. Ray Kim 200 First St. [email protected] Mayo Clinic and Foundation, Rochester, MNSW, Rochester, MN 55905. fax: 507-266-2810.===Search for more papers by this authorRobert S. Brown Jr., Robert S. Brown Jr. Columbia University College of Physicians and Surgeons, New York, NYSearch for more papers by this authorNorah A. Terrault, Norah A. Terrault University of California, San Francisco, San Francisco, CASearch for more papers by this authorHashem El-Serag, Hashem El-Serag Houston VA Medical Center and Baylor College of Medicine, Houston, TXSearch for more papers by this author W. Ray Kim 200 First St., Corresponding Author W. Ray Kim 200 First St. [email protected] Mayo Clinic and Foundation, Rochester, MNSW, Rochester, MN 55905. fax: 507-266-2810.===Search for more papers by this authorRobert S. Brown Jr., Robert S. Brown Jr. Columbia University College of Physicians and Surgeons, New York, NYSearch for more papers by this authorNorah A. Terrault, Norah A. Terrault University of California, San Francisco, San Francisco, CASearch for more papers by this authorHashem El-Serag, Hashem El-Serag Houston VA Medical Center and Baylor College of Medicine, Houston, TXSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.34734Citations: 428AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Bell BP, Navarro VJ, Manos MM, Murphy RC, Leyden WA, St. Louis TE, Kunze K, et al. The epidemiology of newly-diagnosed chronic liver disease in the United States: findings of population-based sentinel surveillance [Abstract]. Hepatology 2001: 34(Part 2): 468A. 2 Murphy S. Deaths: final data for 1998. National vital statistics reports. Hyattsville, MD: National Center for Health Statistics, 2000, Vol. 48. 3 Anonymous. Compressed Mortality File (http://wonder.cdc.gov). Centers for Disease Control and Prevention. (Accessed on March 10, 2002.) 4 El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999: 340: 745– 750.MEDLINE 5 Heffler S, Levit K, Smith S, Smith C, Cowan C, Lazenby H, Freeland M. Health spending growth up In 1999: faster growth expected in the future. Health Affairs 2001: 20: 193– 202.MEDLINE 6 Pagano E, Brunetti M, Tediosi F, Garattini L. Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics 1999: 15: 583– 595.MEDLINE 7 Anonymous. The burden of gastrointestinal diseases. Bethesda, MD: The American Gastroenterologica Association, 2001; 41– 60. 8 Greenfield TK, Rogers JD. Who drinks most of the alcohol in the US? The policy implications. J Studies Alcohol 1999: 60: 78– 89. 9 Grant BG, Harford TC, Dawson DA, Chou P, Dufour MC, Pickering R. Prevalence of DSMIV alcohol abuse and dependence in United States 1992. Alcohol Health Res World 1994; 18: 243– 248. 10 Harwood H, Fountain D, Livermore G. The economic costs of alcohol and drug abuse in the United States 1992. Washington, DC: US Government Printing Office, 1998. 11 Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413– 1419.MEDLINE 12 Chitturi S, Farrell G. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27– 41.MEDLINE 13 Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the US population [Abstract]. Gastroenterology 2001; 120: A65. 14 Falck-Ytter Y, Younossi Z, Marchesini G, McCullough A. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17– 26.MEDLINE 15 Caldwell S, Oelsner D, Iezzoni J, Hespenheide E, Battle E, Driscoll C. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999: 29: 664– 669.MEDLINE 16 Poonawala A, Nair S, Thuluvath P. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689– 692.MEDLINE 17 Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transplantation 2001; 7: 797– 801.MEDLINE 18 Maor-Kendler Y, Batts KP, Burgart LJ, Wiesner RH, Krom RA, Rosen CB, Charlton MR. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000; 70: 292– 297.MEDLINE 19 Teli M, James O, Burt A, Bennett M, Day C. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714– 1719.MEDLINE 20 Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356– 1362.MEDLINE 21 Angulo P, Lindor K. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 81– 88.MEDLINE 22 Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556– 562.MEDLINE 23 Satcher DA. Letter to Citizen. 2000. 24 Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777– 782.MEDLINE 25 Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334– 1340.MEDLINE 26 Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228– 1233.MEDLINE 27 Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virusrelated cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311– 1316.MEDLINE 28 Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91– 96.MEDLINE 29 Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28: 562– 567.MEDLINE 30 Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687– 1695.MEDLINE 31 Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26: 485– 490.MEDLINE 32 McQuillan G, Coleman P, Kruszon-Moran D, Moyer L, Lambert S, Margolis H. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 14– 18.MEDLINE 33 Coleman P, McQuillan G, Moyer L, Lambert S, Margolis H. Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998; 178: 954– 959.MEDLINE 34 Kim W, Dickson E, Lindor K. The impact of liver transplantation and ursodeoxycholic acid on mortality and hospital service utilization in patients with primary biliary cirrhosis in the US [Abstract]. Hepatology 2000; 32: 309A. 35 Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22– 27.MEDLINE 36 Alvarez F, Berg PA, Bianchi FB, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929– 938.MEDLINE 37 Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99– 103.MEDLINE 38 Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355– 1362.MEDLINE 39 Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Int Med 2000; 133: 329– 337. 40 Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275– 278.MEDLINE 41 Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718– 724.MEDLINE 42 Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Int Med 1997; 127: 105– 110. 43 Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Int Med 1998; 129(11S): 946– 953. 44 Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256– 1262.MEDLINE 45 Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 485– 504.MEDLINE 46 Morrison ED, Kowdley KV. Genetic liver disease in adults. Early recognition of the three most common causes. Postgraduate Med 2000; 107: 147– 159. 47 Durand F, Bernuau J, Giostra E, Mentha G, Shouval D, Degott C, Benhamov JP, et al. Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine. Gut 2001; 48: 849– 852.MEDLINE 48 Emre S, Atillasoy EO, Ozdemir S, Schilsky M, Rathna Varma CV, Thung SN, Sternlieb I, et al. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation 2001; 72: 1232– 1236.MEDLINE 49 Eghtesad B, Nezakatgoo N, Geraci LC, Jabour N, Irish WD, Marsh W, Fung JJ, et al. Liver transplantation for Wilson's disease: a single-center experience. Liver Transplantation Surg 1999; 5: 467– 474. 50 Balistreri W. Liver disease in infancy and childhood. In: E Schiff, M Sorrell, W Maddrey, eds. Schiff's Diseases of the Liver. Philadelphia: Lippincott, Williams, and Wilkins, 1998. 51 Ostapowicz G, Fontana R, Navarro V, Chung RT, Torres MB, Atillasoy E, Lee WM, et al. Use of liver transplantation in patients with acute liver failure [Abstract]. Hepatology 2000; 32(Part 2): 215A. 52 Anonymous. 2000 Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data: 1990-1999. Rockville, MD and Richmond, VA: U.S. Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation; United Network for Organ Sharing, 2000. 53 Schiodt F, Atillasoy E, Shakil A, Schiff ER, Caldwell C, Kowdley KV, Stribling R, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transplant Surg 1999; 5: 29– 34. 54 Rakela J, Lange S, Ludwig J, Baldus W. Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc 1985; 60: 289– 292.MEDLINE 55 McCashland T, Shaw B, Tape E. The American experience with transplantation for acute liver failure. Semin Liver Dis 1996; 16: 427– 433.MEDLINE 56 Schiodt F, Rochling F, Casey D, Lee W. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337: 1112– 1117.MEDLINE 57 Anonymous. Hepatitis Surveillance Report. Atlanta, GA: Centers for Disease Control and Prevention, 2000. 58 El-Serag H, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227– 3230.MEDLINE 59 Greenlee R, Hill-Harmon M, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin 2001; 51: 15– 36.MEDLINE 60 Dufour MC. Chronic liver disease and cirrhosis. In: JE. E., ed. Digestive Diseases in the United States: Epidemiology and Impact. Washington, DC: US Government Printing Office, 1994; 613– 646. 61 D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468– 475.MEDLINE 62 Everhart J, Khare M, Hill M, Maurer K. prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999; 117: 632– 639.MEDLINE 63 Everhart J. Gallstones. In: JF Johanson, ed. Gastrointestinal Diseases: Risk Factors and Prevention. Philadelphia: Lippincott-Raven, 1998; 145– 172. 64 Anonymous. Sokol RJ, chair. Pediatric Liver Research Agenda 2000: A Blueprint for the Future. Developed by the Children's Liver Council. American Liver Foundation, 2000. 65 Schwimmer J, Balistreri W. The Transmission, natural history and treatment of hepatitis C virus infection in the pediatric age population. Semin Liver Dis 2000; 20: 37– 46.MEDLINE 66 Bucuvalas J, Ryckman FC, Alonso MP, Balistreri W. Predictors of costs of liver transplantation in children: a single center study. J Pediatr 2001; 139: 66– 74.MEDLINE 67 Balistreri W, Grand R, Suchy F, Ryckman F, Perlmutter D, Sokol R. Biliary atresia: summary of a symposium. Hepatology 1996; 23: 1682– 1697.MEDLINE 68 Bates M, Bucuvalas J, Alonso M, Ryckman F. biliary atresia: pathogenesis and treatment. Semin Hepatol 1998; 18: 281– 294. 69 Laurent J, Gauthier F, Bernard O, Hadchovel M, Odievre M, Valayer J, Alagille D. Long-term outcome after surgery for biliary atresia: study of 40 patients surviving for more than 10 years. Gastroenterology 1990: 99: 1793– 1797.MEDLINE 70 Treem W. Fulminant hepatic failure in children. In: Sokol RJ, chair. Pediatric Liver Research Agenda 2000: A Blueprint for the Future. Developed by the Children's Liver Council. American Liver Foundation, 2000; 64– 72. 71 Sokol R. The chronic disease of childhood obesity: the sleeping giant has awakened. J Pediatr 2000; 136: 711– 713. 72 Strauss R, Barlow S, Dietz W. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136: 727– 733.MEDLINE Citing Literature Volume36, Issue1July 2002Pages 227-242 ReferencesRelatedInformation
Referência(s)